CLEARWATER, Fla., Jan. 31,
2017 /PRNewswire/ -- Bovie Medical Corporation (NYSE MKT:
BVX), provided an update on its J-Plasma® product.
The Company disclosed that it is exploring new sales channel
partnerships to further scale J-Plasma® in the gynecology
specialty. The pilot program with Hologic that expires at the
end of February 2017 will not be
extended as the two companies could not come to a mutually
acceptable financial arrangement.
Additionally, the Company announced that:
- Dr. Vipul Patel, a
world-renowned urologist and leader in robotic surgery, is close to
completing his clinical study of J-Plasma®, with 90% of the
designated patient population already enrolled. Dr. Patel is
examining the benefits of using J-Plasma® for pelvic lymph node
dissection. This procedure is frequently carried out to assess
lymph node metastases following robotic prostatectomies and other
oncological surgeries. The most common side effect of pelvic lymph
node dissection is lymphocele formations, which can cause
post-surgical complications requiring needle aspirations or other
forms of drainage. Dr. Patel's study will determine whether more
precise tools, such as J-Plasma®, could significantly reduce the
formation of lymphoceles.
- Leading experts in plasma medicine at Old
Dominion University published a study in the December, 2016
issue of Plasma Processes and Polymers in which cold plasma from
Bovie's J-Plasma® device was shown in a laboratory model to have
the potential to kill a robust strain of prostate cancer cells and
inhibit their proliferation. For details of the study please click
this link:
http://onlinelibrary.wiley.com/doi/10.1002/ppap.201600108/epdf
The Company will release its fourth quarter and full year 2016
financial results after market on Thursday,
March 9th and hold its analyst/investor
conference call to discuss its financial performance and latest
J-Plasma® developments on Friday morning, March 10th.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented new
plasma-based surgical product for cutting and coagulation.
J-Plasma® utilizes a helium ionization process to produce a stable,
focused beam of ionized gas that provides surgeons with greater
precision, minimal invasiveness and an absence of conductive
currents through the patient during surgery. Bovie Medical
Corporation is also a leader in the manufacture of a range of
electrosurgical products and technologies, marketed through both
private labels and the Company's own well-respected brands (Bovie®,
Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company's current and new products,
please refer to the Investor Relations section of Bovie Medical
Corporation's www.boviemed.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bovie-medical-provides-j-plasma-update-300399799.html
SOURCE Bovie Medical Corporation